Plant factories for the production of monoclonal antibodies
- 作者: Sheshukova E.V.1, Komarova T.V.1,2, Dorokhov Y.L.1,2
- 
							隶属关系: 
							- Vavilov Institute of General Genetics
- Belozersky Institute of Physico-Chemical Biology
 
- 期: 卷 81, 编号 10 (2016)
- 页面: 1118-1135
- 栏目: Review
- URL: https://journals.rcsi.science/0006-2979/article/view/151038
- DOI: https://doi.org/10.1134/S0006297916100102
- ID: 151038
如何引用文章
详细
Like animal cells, plant cells bear mechanisms for protein synthesis and posttranslational modification (glycosylation and phosphorylation) that allow them to be seriously considered as factories for therapeutic proteins, including antibodies, with the development of biotechnology. The plant platform for monoclonal antibody production is an attractive approach due to its flexibility, speed, scalability, low cost of production, and lack of contamination risk from animal-derived pathogens. Contemporary production approaches for therapeutic proteins rely on transgenic plants that are obtained via the stable transformation of plant cells as well as the transient (temporary) expression of foreign proteins. In this review, we discuss present-day approaches for monoclonal antibody production in plants (MAPP), features of carbohydrate composition, and methods for the humanization of the MAPP carbohydrate profile. MAPPs that have successfully passed preclinical studies and may be promising for use in clinical practice are presented here. Perspectives on using MAPPs are determined by analyzing their economic benefits and production rates, which are especially important in personalized cancer therapy as well as in cases of bioterrorism and pandemics.
作者简介
E. Sheshukova
Vavilov Institute of General Genetics
														Email: dorokhov@genebee.msu.su
				                					                																			                												                	俄罗斯联邦, 							Moscow, 119991						
T. Komarova
Vavilov Institute of General Genetics; Belozersky Institute of Physico-Chemical Biology
														Email: dorokhov@genebee.msu.su
				                					                																			                												                	俄罗斯联邦, 							Moscow, 119991; Moscow, 119991						
Y. Dorokhov
Vavilov Institute of General Genetics; Belozersky Institute of Physico-Chemical Biology
							编辑信件的主要联系方式.
							Email: dorokhov@genebee.msu.su
				                					                																			                												                	俄罗斯联邦, 							Moscow, 119991; Moscow, 119991						
补充文件
 
				
			 
						 
						 
					 
						 
						 
				 
  
  
  
  
  电邮这篇文章
			电邮这篇文章  开放存取
		                                开放存取 ##reader.subscriptionAccessGranted##
						##reader.subscriptionAccessGranted## 订阅存取
		                                		                                        订阅存取
		                                					